$18.04
-0.15[-0.82%]
Last update: 12:40PM Get Real Time Here
Guardant Health
(NASDAQ:GH)Guardant Health Stock (NASDAQ:GH), Analyst Ratings, Price Targets, Predictions
Guardant Health Inc has a consensus price target of $55.77, established from looking at the 62 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, Craig-Hallum, and Goldman Sachs on April 29, 2024, April 24, 2024, and April 15, 2024. With an average price target of $28.67 between Canaccord Genuity, Craig-Hallum, and Goldman Sachs, there's an implied 58.91% upside for Guardant Health Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Craig-Hallum
Goldman Sachs
Guggenheim
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Guardant Health
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/29/2024 | GH | Buy Now | Guardant Health | $18.04 | 66.3% | Canaccord Genuity | Kyle Mikson | $45 → $30 | Maintains | Buy | Get Alert |
| 04/24/2024 | GH | Buy Now | Guardant Health | $18.04 | 55.21% | Craig-Hallum | Alex Nowark | → $28 | Assumes | → Buy | Get Alert |
| 04/15/2024 | GH | Buy Now | Guardant Health | $18.04 | 55.21% | Goldman Sachs | Matthew Sykes | $32 → $28 | Maintains | Buy | Get Alert |
| 04/05/2024 | GH | Buy Now | Guardant Health | $18.04 | — | Guggenheim | Subbu Nambi | — | Reiterates | → Neutral | Get Alert |
| 02/26/2024 | GH | Buy Now | Guardant Health | $18.04 | 66.3% | Piper Sandler | David Westenberg | $40 → $30 | Maintains | Overweight | Get Alert |
| 02/23/2024 | GH | Buy Now | Guardant Health | $18.04 | 149.45% | JP Morgan | Julia Qin | $60 → $45 | Maintains | Overweight | Get Alert |
| 02/23/2024 | GH | Buy Now | Guardant Health | $18.04 | 149.45% | Canaccord Genuity | Kyle Mikson | $50 → $45 | Maintains | Buy | Get Alert |
| 01/30/2024 | GH | Buy Now | Guardant Health | $18.04 | 105.1% | Goldman Sachs | Matthew Sykes | $43 → $37 | Maintains | Buy | Get Alert |
| 01/29/2024 | GH | Buy Now | Guardant Health | $18.04 | 105.1% | Goldman Sachs | Matthew Sykes | $43 → $37 | Maintains | Buy | Get Alert |
| 12/14/2023 | GH | Buy Now | Guardant Health | $18.04 | — | Guggenheim | Subbu Nambi | — | Initiates | → Neutral | Get Alert |
| 12/13/2023 | GH | Buy Now | Guardant Health | $18.04 | — | Wolfe Research | Doug Schenkel | — | Initiates | → Peer Perform | Get Alert |
| 11/13/2023 | GH | Buy Now | Guardant Health | $18.04 | 49.67% | Raymond James | Andrew Cooper | → $27 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/08/2023 | GH | Buy Now | Guardant Health | $18.04 | 177.16% | Morgan Stanley | Shannon O'Callaghan | $55 → $50 | Maintains | Overweight | Get Alert |
| 10/23/2023 | GH | Buy Now | Guardant Health | $18.04 | 149.45% | Goldman Sachs | Matthew Sykes | $52 → $45 | Maintains | Buy | Get Alert |
| 10/20/2023 | GH | Buy Now | Guardant Health | $18.04 | 149.45% | Goldman Sachs | Matthew Sykes | $52 → $45 | Maintains | Buy | Get Alert |
| 10/02/2023 | GH | Buy Now | Guardant Health | $18.04 | 177.16% | Citigroup | Patrick Donnelly | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/28/2023 | GH | Buy Now | Guardant Health | $18.04 | 88.47% | Bernstein | Eve Burstein | → $34 | Initiates | → Outperform | Get Alert |
| 09/27/2023 | GH | Buy Now | Guardant Health | $18.04 | 121.73% | Piper Sandler | David Westenberg | → $40 | Upgrade | Neutral → Overweight | Get Alert |
| 08/08/2023 | GH | Buy Now | Guardant Health | $18.04 | 121.73% | Piper Sandler | David Westenberg | $30 → $40 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Guardant Health (GH)?
The latest price target for Guardant Health (NASDAQ: GH) was reported by Canaccord Genuity on April 29, 2024. The analyst firm set a price target for $30.00 expecting GH to rise to within 12 months (a possible 66.30% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Guardant Health (GH)?
The latest analyst rating for Guardant Health (NASDAQ: GH) was provided by Canaccord Genuity, and Guardant Health maintained their buy rating.
When was the last upgrade for Guardant Health (GH)?
The last upgrade for Guardant Health Inc happened on November 13, 2023 when Raymond James raised their price target to $27. Raymond James previously had a market perform for Guardant Health Inc.
When was the last downgrade for Guardant Health (GH)?
The last downgrade for Guardant Health Inc happened on May 1, 2023 when OTR Global changed their price target from N/A to N/A for Guardant Health Inc.
When is the next analyst rating going to be posted or updated for Guardant Health (GH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Guardant Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Guardant Health was filed on April 29, 2024 so you should expect the next rating to be made available sometime around April 29, 2025.
Is the Analyst Rating Guardant Health (GH) correct?
While ratings are subjective and will change, the latest Guardant Health (GH) rating was a maintained with a price target of $45.00 to $30.00. The current price Guardant Health (GH) is trading at is $18.04, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.